B. Merola et al., CV-205-502 IN THE TREATMENT OF TUMORAL AND NONTUMORAL HYPERPROLACTINEMIC STATES, Biomedicine & pharmacotherapy, 48(3-4), 1994, pp. 167-174
Citations number
27
Categorie Soggetti
Pharmacology & Pharmacy","Medicine, Research & Experimental
CV 205-502 (octahydrobenzol[g]quinoline), a non-ergot dopamine a,oonis
t drug, was administered to 40 patients with hyperprolactinemic syndro
me: 16 patients with macroprolactinoma, 14 with microprolactinoma and
10 with non-tumoral hyperprolactinemia. Twenty-four out of 40 patients
had previously been treated by surgery and/or bromocriptine, with var
iable results. All had gonadal dysfunction and 22 patients had galacto
rrhea. Eight patients with macroprolactinoma had defects of the visual
field. Pre-treatment serum PRL levels ranged from 60 to 2050 mu g/l.
The daily dose of CV 205-502 used in this trial ranged from 0.075 to 0
.600 mg. After 6-12 months of treatment, serum PRL level decreased in
all the patients reaching normoprolactinemia in 31 of them (77.5%) who
demonstrated restoration of menses and disappearance of galactorrhea.
The remaining nine patients (22.5%) had only a decrease of PRL levels
without reaching normoprolactinemia and without any clinical effect.
In 12 out of 16 patients with macroprolactinoma not previously surgica
lly treated, a significant tumor shrinkage was shown by means of Compu
ted Tomography and/or Magnetic Resonance Imaging. The disappearance of
visual defects was obtained in four out of eight patients. CV 205-502
was tolerated satisfactorily: mild side-effects occurred in four pati
ents in the first week of treatment and spontaneously disappeared, whe
reas six patients (15%) needed to withdraw the therapy after 6 months
because of side-effects. In conclusion CV 205-502 is a potent and well
-tolerated drug in the treatment of tumoral and non-tumoral hyperprola
ctinemic states and is an effective alternative to other dopamine agon
ists in use today.